InspireMD, Inc.

NasdaqCM:NSPR Stock Report

Market Cap: US$45.0m

InspireMD Management

Management criteria checks 3/4

InspireMD's CEO is Marvin Slosman, appointed in Jan 2020, has a tenure of 6.42 years. total yearly compensation is $3.10M, comprised of 19% salary and 81% bonuses, including company stock and options. directly owns 0.081% of the company’s shares, worth $36.22K. The average tenure of the management team and the board of directors is 2.4 years and 6.4 years respectively.

Key information

Marvin Slosman

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage19.01%
CEO tenure6.4yrs
CEO ownership0.08%
Management average tenure2.4yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

Analysis Article • Dec 24

Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jan 11

Here's Why We're Not Too Worried About InspireMD's (NASDAQ:NSPR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. By way of example, InspireMD...
Analysis Article • Jan 27

We Think InspireMD (NASDAQ:NSPR) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Oct 05

We're Keeping An Eye On InspireMD's (NASDAQ:NSPR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 20

InspireMD: Revolutionizing The Field Of Vascular Stenting

InspireMD develops and commercializes proprietary stent designs with a proprietary mesh. The Company seeks to change the SoC in the treatment of CAD and other invasive indications utilizing an integrated embolic protection stent platform. The Company’s commercialized products are CE mark approved but not approved for sale in the U.S. The Company has initiated a U.S. registrational IDE clinical trial for CGuard EPS in July 2021.
Analysis Article • Feb 11

Trade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares

Investors who take an interest in InspireMD, Inc. ( NYSEMKT:NSPR ) should definitely note that insider Gary Roubin...

CEO Compensation Analysis

How has Marvin Slosman's remuneration changed compared to InspireMD's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$51m

Dec 31 2025US$3mUS$589k

-US$49m

Sep 30 2025n/an/a

-US$46m

Jun 30 2025n/an/a

-US$41m

Mar 31 2025n/an/a

-US$36m

Dec 31 2024US$3mUS$550k

-US$32m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$3mUS$470k

-US$20m

Sep 30 2023n/an/a

-US$19m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$18m

Dec 31 2022US$697kUS$433k

-US$18m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$2mUS$410k

-US$15m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$1mUS$367k

-US$11m

Compensation vs Market: Marvin's total compensation ($USD3.10M) is above average for companies of similar size in the US market ($USD635.09K).

Compensation vs Earnings: Marvin's compensation has been consistent with company performance over the past year.

CEO

Marvin Slosman (62 yo)

6.4yrs
Tenure
US$3,095,187
Compensation

Mr. Marvin L. Slosman is Independent Director of BioCardia, Inc. from December 2, 2025. He has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman ser...

Leadership Team

NamePositionTenureCompensationOwnership
Marvin Slosman
President6.4yrsUS$3.10m0.081%
$ 36.2k
Michael Lawless
CFO, Secretary & Treasurer1yrUS$1.87m1.48%
$ 664.1k
Shane Gleason
Chief Commercial Officer2.8yrsUS$1.45m2.25%
$ 1.0m
Donna DeChant
Vice President of Human Resources & Organizational Developmentno datano datano data
Amir Kohen
Executive VP of Finance & Regional Manager1.4yrsno datano data
Peter Ligotti
Executive VP & GM of North America2.4yrsno data0.66%
$ 295.0k
Peter Soukas
Chief Medical Officerless than a yearno datano data
Sol Barer
Special Advisor to the Boardno dataUS$13.92kno data
2.4yrs
Average Tenure
59.5yo
Average Age

Experienced Management: NSPR's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marvin Slosman
President6.4yrsUS$3.10m0.081%
$ 36.2k
Michael Berman
Independent Director13.3yrsUS$186.92k1.28%
$ 573.7k
Daniel Dearen
Independent Directorless than a yearUS$200.89k0.22%
$ 98.0k
Elazer Edelman
Member of Advisory Boardno datano datano data
Antonio Colombo
Member of Advisory Boardno datano datano data
Alexandre Abizaid
Member of Advisory Boardno datano datano data
Martin B. Leon
Member of Advisory Boardno datano datano data
Eberhart Grube
Member of Advisory Boardno datano datano data
Paul Stuka
Independent Chairman of the Board14.8yrsUS$290.26k1.43%
$ 641.2k
Kenneth Rosenfield
Chair of Scientific Advisory Board5.2yrsno datano data
Yaron Almagor
Member of Advisory Boardno datano datano data
Edo Kaluski
Member of Advisory Boardno datano datano data
6.4yrs
Average Tenure
68yo
Average Age

Experienced Board: NSPR's board of directors are considered experienced (6.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/04 12:56
End of Day Share Price 2026/06/04 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InspireMD, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Keay NakaeChardan Capital Markets, LLC
Jose De Jesus HarescoCitizens JMP Securities, LLC